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TRENDS IN INPATIENT COSTS FOR ACUTE 
PANCREATITIS IN THE UNITED STATES
Bell CF, Stephens JM, Botteman MF, Pashos CL, Ewing M
Abt Associates Clinical Trials, Bethesda, MD, USA
Although the care of patients with pancreatitis-related
complications is estimated to be much more resource-
intensive than that provided to other critically-ill patients,
information on the cost of acute pancreatitis is limited.
OBJECTIVES: To examine trends in the incidence and
cost of acute pancreatitis-related hospitalizations in the
United States, and to ascertain patient disposition at dis-
charge to evaluate the extent to which costs may extend
beyond the initial hospitalization. METHODS: Data
were obtained from the 1995–1997 Health care Cost and
Utilization Project database. ICD-9-CM code 577.0 was
used to identify hospitalizations with a primary or sec-
ondary diagnosis of acute pancreatitis. Patient demo-
graphics, length of stay (LOS), total charges (in constant
1995 dollars), and discharge status were assessed. RE-
SULTS: Between 1995 and 1997, the number of acute
pancreatitis-related hospitalizations increased by 9.1%
from 241,178 to 263,136. During that period, the aver-
age LOS decreased by 9.5% from 8.4 days to 7.6 days
and the mean hospital charges decreased by 4.9% from
$19,222 to $18,280. Using LOS 15 days as a proxy for
severity, severe acute pancreatitis-related hospital dis-
charges decreased from 30,444 in 1995 to 27,839 in
1997. During that period, the average LOS remained
constant (28.9–28.4 days) and the mean charges in-
creased from $77,572 to $82,043. Nationwide, the pro-
jected pancreatitis-related inpatient charges have in-
creased from $4.6 to $4.8 billion. Despite representing
12% of admissions, severe acute pancreatitis-related
charges represented 49% of all acute pancreatitis-related
inpatient charges. 38–41% of patients were discharged to
another facility, suggesting that these cost estimates are
conservative. CONCLUSIONS: Acute pancreatitis is a
major financial burden on health care systems due to
high inpatient costs and frequent need for medical care
that extends beyond the hospital stay. Despite a reduc-
tion in charge per case, total inpatient charges of pancre-
atitis have increased to rising incidence.
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It is necessary to understand the direct and indirect costs
of HIV infection in untreated workers in order to esti-
mate the value of aggressive antiretroviral therapies from
an employer’s perspective. Currently the cost of HIV/
AIDS from an employer’s perspective is not well under-
stood. OBJECTIVES: To estimate lifetime costs of HIV
infection in untreated employees from an employer’s per-
spective. METHODS: A simulation model was developed
to predict costs of HIV infection in untreated employees
from an employer’s perspective over a ten-year time
frame. This model utilized age, CD4 cell counts, and
plasma HIV-1 RNA level as major predictors of disease
progression and expected patient survival to estimate life-
time costs. Major direct cost components were health in-
surance premium, life insurance premium, short-term dis-
ability benefits, long-term disability benefits, and hiring/
training expenses. The indirect cost included productivity
loss at work. RESULTS: For a hypothetical 35-year old
HIV-positive employee with CD4 cell counts at 380
cells/mm3 and HIV-1 RNA at 22,000 copies/ml, the
model estimated that the total direct and indirect costs of
HIV infection was $165,873 from the employer’s per-
spective over a 10-year period. This included $66,659 for
health insurance, $12,788 for life insurance costs, $8,580
for short-term and long-term disability benefits, $25,894
for hiring and training expenses and $51,952 due to pro-
ductivity loss. Sensitivity analyses suggested that changes
in employee age, CD4 cell count, HIV-1 RNA viral
load, and CD4 cell decline rate were important param-
eters that significantly impact the costs of untreated HIV
workers to employers. CONCLUSION: Without effec-
tive antiretroviral therapy, HIV infection could result in
significant direct and indirect costs to employers. There-
fore, the cost-effectiveness of treatment with advanced
antiretroviral regimen should be considered for HIV in-
fected workers.
PID5
MOXIFLOXACIN VS AMOXICILLIN/
CLAVULANATE IN THE TREATMENT OF ACUTE 
MAXILLARY SINUSITIS (AMS):
EFFICACY, SAFETY AND PATIENT-REPORTED
OUTCOMES IN PRIMARY CARE
Rakkar S
Plano Medical Center, Plano, TX, USA
OBJECTIVE: This study was designed to reflect real-
world experience in the treatment of patients with AMS.
Efficacy, safety, and patient-reported outcomes variables
were compared between moxifloxacin (MXF) and amox-
icillin/clavulanate (AC) for the management of AMS in a
primary care setting. METHODS: In this prospective,
multicenter, non-blinded phase IIIb trial, 475 adult pa-
tients with symptoms of AMS were randomized to re-
ceive a 10-day oral regimen of either MXF (400mg once-
daily) or AC (875mg twice-daily). Clinical success at the
test-of-cure (TOC) visit (post-therapy days 14–21) was
the primary efficacy measure. Secondary outcomes in-
cluded rate of clinical relapse at follow-up (post-therapy
days 26–46) and exploratory evaluation of patient-
reported outcomes variables. Safety data was also tabu-
lated from intent-to-treat (ITT) patients. RESULTS: Of
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471 adults comprising the ITT population (234 MXF,
237 AC), MXF treatment was statistically equivalent to
AC at the TOC visit (85.2% vs 81.8%; 95%CI 
6%,13%). Per-protocol analysis also confirmed statisti-
cal equivalence between MXF and AC (86.5% vs 83.6%;
95%CI  7%,13%). Rates of relapse were similar for
the ITT (4% MXF, 5% AC) and the per-protocol (4%
both) populations. The frequency of drug-related adverse
events were similar between MXF (30%) and AC (25%)
and were primarily gastrointestinal-related: nausea (11%
MXF, 5% AC) and diarrhea (3% MXF, 10% AC). At
the TOC visit, significantly more MXF-treated patients
(n  47; 24%) in the ITT population than AC-treated
patients (n  28; 14%) reported symptomatic improve-
ment by day 3 (p  0.02). No differences existed in terms
of lost work hours or time to return to normal activities
between treatment groups. CONCLUSIONS: In this pri-
mary care clinical trial, once-daily MXF was as effective
and safe as twice-daily AC in the treatment of AMS. In
some patients, MXF was associated with more rapid
symptomatic relief, which has potential clinical and so-
cioeconomic implications.
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HIV/AIDS HEALTH STATE UTILITIES USING 
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WEIGHTS: WHEN DOES IT MATTER?
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OBJECTIVES: To compare utilities for HIV/AIDS health
states derived from community-based preferences with
those derived from patients, and to examine the implica-
tions of differences for a cost-effectiveness analysis of
early versus deferred treatment of HIV patients present-
ing with CD4 cell counts of 500/L. METHODS: We
used data from the HIV Cost and Services Utilization
Study (HCSUS), a probability sample of 2,864 HIV-
infected adults receiving care in the United States in 1996,
to derive utilities for HIV/AIDS health states. Commu-
nity-based utilities were calculated from the SF-6D re-
sponses in the HCSUS survey using algorithms derived by
Brazier et al. Patient utilities were calculated from patient
self-assessments using a rating scale transformation de-
rived by Torrance et al. We used a computer-based state-
transition simulation model of HIV disease to conduct
cost-effectiveness analyses using both community and pa-
tient utilities. RESULTS: Patient utilities were signifi-
cantly higher (by 4% to 9%, p  0.001) than community
utilities for all disease stages: for asymptomatic HIV pa-
tients 0.970 (0.963–0.977) vs. 0.937 (0.926–0.949); for
symptomatic HIV patients 0.910 (0.902–0.919) vs. 0.841
(0.826–0.855); and for patients with a history of an
AIDS-defining condition 0.845 (0.832–0.858) vs. 0.778
(0.761–0.795). The cost-effectiveness ratio of early ther-
apy (initiated at 500 CD4 cells/L) versus deferred ther-
apy (initiated at 200 CD4 cells/L) was $20,100/QALY
using community utilities and $18,400/QALY using pa-
tient utilities. In a sensitivity analysis, when we assumed a
20% reduction in quality of life due to side effects during
early therapy but not during deferred therapy, the cost-
effectiveness ratio of early versus deferred therapy was
$50,900/QALY using community utilities and $46,300/
QALY using patient utilities. CONCLUSIONS: There
are differences between community and patient utilities
for HIV/AIDS health states. The impact of these differ-
ences on HIV/AIDS cost-effectiveness results should be
considered when treatment side effects are important.
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OBSERVATIONAL EVALUATION OF HEALTH 
STATE UTILITIES AMONG A COHORT OF 
SEPSIS PATIENTS
Drabinski A, Williams G, Formica C
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
OBJECTIVE: Among sepsis survivors, during recovery
and thereafter, it is not established if patients resume or
improve their quality of life. The study objective was to
assess change in health status among sepsis survivors
over a 6-month period. METHODS: This was a prospec-
tive, multicenter, cohort study involving 701 patients
with severe sepsis of presumed infectious origin from 53
hospitals. Patients’ health status was assessed at day 30,
60, 90 and180 using EuroQoL-5D and a visual analog
scale. Instruments were completed by the patient while in
hospital and follow-up assessments were performed by
telephone interview. RESULTS: For this interim analysis,
93 patients had completed health state information for
day 30, 60, 90, and 180. Mean (SD) age was 60  17
years and 48% were female. The number of patients re-
maining in the hospital decreased from 56% at day 30 to
7%, thereafter. The average utility score/VAS score at
each time point was: 0.53/0.61 (day 30), 0.62/0.68 (day
60), 0.68/0.71 (day 90), 0.69 (p  0.0001)/0.72 (day
180). Based on patients’ subjective assessment of their
health status during the last 12 months, 60% had im-
proved or maintained their health. The improvement in
utility scores was influenced primarily by changes in mo-
bility, self-care, and usual activities. Pain and anxiety ap-
peared to have a minimal influence on overall improve-
ment in health status. At day 30, 28% of the patients
reported no problems in walking, compared to 58% at
day 180. Likewise, 48% and 26% of patients reported no
problems with self-care and performing usual activities at
day 30, respectively, and 67% (self-care) and 47% (usual
activities) at day 180. CONCLUSION: Sepsis survivors
experienced a continual improvement towards popula-
tion-based normal levels in their health utility scores over
a 6-month period. Improvements in physical activity,
self-care and usual activities were predominantly associ-
ated with improved health utility.
